{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:34Z","timestamp":1790198494838,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T00:00:00Z","timestamp":1271721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12185-010-0565-1","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T00:01:55Z","timestamp":1271635315000},"page":"799-807","source":"Crossref","is-referenced-by-count":54,"title":["Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion"],"prefix":"10.1007","volume":"91","author":[{"given":"Yasunobu","family":"Nagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiomi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,20]]},"reference":[{"key":"565_CR1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"565_CR2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Kantarjian HM, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200\u20136.","journal-title":"Leukemia"},{"key":"565_CR3","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658\u201361.","journal-title":"J Med Chem"},{"key":"565_CR4","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood-2009-06-226720","volume":"114","author":"SE McKenzie","year":"2009","unstructured":"McKenzie SE, Reilly MP. The clot thickens (or not). Blood. 2009;114:1722\u20133.","journal-title":"Blood"},{"key":"565_CR5","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cncr.24155","volume":"115","author":"HJ Khoury","year":"2009","unstructured":"Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer. 2009;115:1381\u201394.","journal-title":"Cancer"},{"key":"565_CR6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100\u00a0mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377\u201386.","journal-title":"Cancer"},{"key":"565_CR7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","volume":"176","author":"A Bergeron","year":"2007","unstructured":"Bergeron A, R\u00e9a D, Rousselot P, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176:814\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"565_CR8","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"565_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Lipton JH, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135\u20139.","journal-title":"Haematologica"},{"key":"565_CR10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s12185-009-0290-9","volume":"89","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Kakihana K, Ohashi K, Yamaguchi T, Tadokoro K, Akiyama H, et al. Serial monitoring of T315I BCR-ABL mutation by invader assay combined with RT-PCR. Int J Hematol. 2009;89:482\u20138.","journal-title":"Int J Hematol"},{"key":"565_CR11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2141.2009.07666.x","volume":"145","author":"F Gruber","year":"2009","unstructured":"Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2009;145:581\u201397.","journal-title":"Br J Haematol"},{"key":"565_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1078155208094455","volume":"15","author":"SF Wong","year":"2009","unstructured":"Wong SF. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia. J Oncol Pharm Pract. 2009;15:17\u201327.","journal-title":"J Oncol Pharm Pract"},{"key":"565_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","volume":"4","author":"K Kelly","year":"2009","unstructured":"Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4:99\u2013105.","journal-title":"Target Oncol"},{"key":"565_CR14","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol"},{"key":"565_CR15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","volume":"141","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745\u20137.","journal-title":"Br J Haematol"},{"key":"565_CR16","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","volume":"23","author":"FJ Giles","year":"2009","unstructured":"Giles FJ, O\u2019Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009;23:1698\u2013707.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0565-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0565-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0565-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:01:32Z","timestamp":1559437292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0565-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,20]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0565-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,20]]}}}